Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19
Elizabeth E Zumbrun, Chengzi I Kaku, Lukas Dillinger, Samantha E Zak, Ana I Kuehne, Russel R Bakken, Jeffrey W Koehler, Korey L Delp, Christopher P Stefan, Raina Kumar, Jeffrey R Kugelman, Alicia M Moreau, Xiankun Zeng, John M Dye, Andrew S Herbert, Kristin Narayan, Laura M Walker
Antimicrobial Agents and Chemotherapy, doi:10.1128/aac.01353-22
Adintrevimab is a human immunoglobulin G1 monoclonal antibody engineered to have broad neutralization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and other SARS-like coronaviruses with pandemic potential. In both Syrian golden hamster and rhesus macaque models, prophylactic administration of a single dose of adintrevimab provided protection against SARS-CoV-2/WA1/2020 infection in a dose-dependent manner, as measured by significant reductions in lung viral load and virus-induced lung pathology, and by inhibition of viral replication in the upper and lower respiratory tract.
References
Andrews, Stowe, Kirsebom, Toffa, Rickeard et al., COVID-19 vaccine effectiveness against the Omicron (B.1.1.529) variant, N Engl J Med,
doi:10.1056/NEJMoa2119451Dejnirattisai, Huo, Zhou, Zahradník, Supasa et al., SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses,
doi:10.1016/j.cell.2021.12.046Imai, Iwatsuki-Horimoto, Hatta, Loeber, Halfmann et al., Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development, Proc Natl Acad Sci U S A,
doi:10.1073/pnas.2009799117Kaku, Narayan, Schmidt, Engler, Li et al., ADG20, a half-life-extended monoclonal antibody in development for the prevention and treatment of COVID-19, demonstrated broad in vitro neutralisation against SARS-CoV-2 variants
Liu, Ginn, Dejnirattisai, Supasa, Wang et al., Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum, Cell,
doi:10.1016/j.cell.2021.06.020Liu, Iketani, Guo, Chan, Wang et al., Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2, Nature,
doi:10.1038/s41586-021-04388-0Martinez, Schäfer, Gobeil, Li, De La Cruz et al., A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice, Sci Transl Med,
doi:10.1126/scitranslmed.abj7125Osterrieder, Bertzbach, Dietert, Abdelgawad, Vladimirova et al., Age-dependent progression of SARS-CoV-2 infection in Syrian hamsters, Viruses,
doi:10.3390/v12070779Rappazzo, Tse, Kaku, Wrapp, Sakharkar et al., Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody, Science,
doi:10.1126/science.abf4830Rogers, Zhao, Huang, Beutler, Burns et al., Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model, Science,
doi:10.1126/science.abc7520Vegivinti, Evanson, Lyons, Akosman, Barrett et al., Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials, BMC Infect Dis,
doi:10.1186/s12879-022-07068-0Who, Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update, WHO
